Plain-English translation of NCT07524114 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →SHERLOCK is a research platform designed to test whether a simple blood test can detect tiny amounts of cancer that may remain after treatment. The study enrolls 7,000 patients with various cancer types who have completed curative treatments like surgery, chemotherapy, or radiation. Researchers will use advanced blood tests to look for circulating tumor DNA—genetic material from cancer cells—to see if this approach can catch cancer recurrence earlier than current methods.
Current imaging tests sometimes miss early signs of cancer recurrence. This treatment aims to fill that gap by detecting cancer much earlier through blood tests alone, potentially allowing doctors to intervene before cancer becomes advanced again.
You likely qualify if…
You likely don't qualify if…
You will have blood samples drawn at regular visits while you receive or have recently completed your cancer treatment. The study team will also collect information about your cancer type, treatment, and medical history. Some patients may be invited to join additional clinical trials if blood tests show signs of residual disease. Throughout the study, you'll have imaging scans and ongoing blood tests to monitor whether any cancer traces clear over time.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Canada